Biogen Inc. has finally announced a new CEO, six months after Michel Vounatsos said he would be stepping down.
Christopher Viehbacher, a longtime executive at GSK plc (NYSE: GSK) and former CEO of Sanofi ADR (Nasdaq: SNY), will take the corner office at the Cambridge biotech (Nasdaq: BIIB). He will start on Nov. 14.
“It is both an honor and an exciting opportunity to join the Biogen team. I greatly admire Biogen for its determination and resilience in pioneering important new medicines to address…
